From June 16-19, 2025, the 2025 BIO International Convention (“BIO 2025”) was held at the Boston Convention & Exhibition Center in Boston, Massachusetts, USA. Marking its seventh consecutive year at the conference, Henlius showcased a wide range of innovative research and development accomplishments, attracting significant attention from numerous attendees and organizations. During the conference, Henlius held around 130 in-depth meetings, driving exchanges on collaboration opportunities for in-licensing, research collaboration, or commercial right out-licensing.
Ping Cao, Henlius SVP and Chief Business Development Officer, emphasized in her BIO keynote: Henlius has delivered on its mission to provide high-quality and affordable biologics since inception, benefiting over 800,000 patients globally while achieving end-to-end value integration from R&D to commercialization. Simon Hsu, CTO and SVP of Henlius, highlighted breakthroughs in AI-driven drug development, demonstrating how Henlius' double engines of innovation and accessibility fuel its global competitiveness. Additionally, at the 'BIO CHINA Global Forum 2025@Boston' co-hosted by Henlius, the company's executives engaged in in-depth discussions with global partners Accord, Dr. Reddy's, Palleon, Organon, and Sermonix on strategic drivers for global partnerships with Chinese biopharma, showcasing our international footprint. The dialogue sparked significant industry attention and further amplified the company's global influence in the biologics market.
Henlius anchors its strategy in unmet patient needs, powers progress through continuous innovation and advances its global presence with manufacturing and quality systems, as well as commercialization capabilities, delievering the goals of providing innovative and affordable biologics for global patients. The company has expanded its global market presence with several products, including HANQUYOU, HANSIZHUANG, HANLIKANG, HLX11, HLX14, and HLX15, in collaboration with renowned international biopharmaceutical companies such as Accord, Abbott, Dr.Reddy’s, Eurofarma, KGbio, Sandoz and Organon. It has achieved comprehensive coverage in the mainstream biopharmaceutical markets of Europe, the United States, and numerous emerging markets, contributing to the global development of China's biopharmaceutical innovation.
Henlius’ self-developed and manufactured trastuzumab biosimilar HANQUYOU (trade name: HERCESSI™ in U.S. and Zercepac® in Europe) is a China-developed mAb biosimilar approved in China, Europe, and U.S. It has been approved in over 50 countries and regions, covering China, Southeast Asia, North America, the EU, Middle East, and Latin America, benefiting over 250,000 patients. Additionally, the company prides itself on its HANSIZHUANG (serplulimab, trade name: Hetronifly ® in Europe), the world's first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC), and it has been approved in more than 30 countries and regions, including China, the EU, and Southeast Asia. To date, Orphan Drug Designation (ODD) granted to HANSIZHUANG for the treatment of SCLC by U.S. FDA, EC, and Swissmedic, and for Extensive-Stage SCLC (ES-SCLC) by Korea MFDS. Meanwhile, the company is efficiently advancing the clinical progress of its innovative product portfolio. The phase 3 international multicentre clinical trails of Henlius' novel anti-HER2 mAb, HLX22, is being conducted simultaneously across China, Australia, the European Union, Japan, the United States, South America, and other countries and regions. Recently, the first subject has been dosed for a phase 2 international muticenter clinical trial of HLX43（PD-L1 ADC）, another company’s potential first/best-in-class products. At present, HLX43 is the first PD-L1 ADC progressed to phase 2 clinical trial development globally.
Looking forward, Henlius will continue to collaborate closely with global partners, leveraging innovation and cooperation, to deliver more high-quality, affordable treatment options to patients worldwide.
